A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered EQ121 Following Single and Multiple Doses in Healthy Adult Volunteers
Latest Information Update: 16 Sep 2021
Price :
$35 *
At a glance
- Drugs LNK 01001 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors EQRx
- 16 Sep 2021 New trial record